ReviewMayo Clinic proceedings2017
Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.
Review in Mayo Clinic proceedings, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.Blood advances · 2025Trial
- RFC1 Repeat Expansions in Chronic Idiopathic Axonal Polyneuropathy: Prevalence, Phenotype, and Diagnostic Implications.Journal of the peripheral nervous system : JPNS · 2026Observational
- The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma.Life (Basel, Switzerland) · 2026Review
- Monoclonal gammopathy of clinical significance: a multisystem review.Blood cancer journal · 2026Review
- Monoclonal Gammopathy of Neurological Significance: Toward an Integrated Hematologic-Neurologic Perspective-A Single-Center Retrospective Study.International journal of molecular sciences · 2026Article
- Clinical Utility of Routine Monoclonal Gammopathy Testing in the Evaluation of Peripheral Neuropathy.Journal of general internal medicine · 2026Article
- Estimated Whole Blood Viscosity in Smoldering Multiple Myeloma: Preliminary Data from a Retrospective Single Center Analysis.Journal of blood medicine · 2026Article
- Monoclonal Gammopathy in Amyotrophic Lateral Sclerosis: No Impact on Clinical Progression and Immunotherapy Outcomes.European journal of neurology · 2025Article
- Article
- Pathologic and Therapeutic Schwann Cells.Cells · 2025Review
- Plasma cell myeloma with an evolving diagnostic complexity: A case report.Oncology letters · 2025Article
- Association of co-existing vitamin B6 and B12 deficiency with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome: a case report.BMC neurology · 2025Article
- Neurological manifestations of MGUS.Hematology. American Society of Hematology. Education Program · 2024Review
- Clinical Spectrum of Monoclonal Protein and the Factors Associated with Lymphoplasmacytic Malignancies.Journal of clinical medicine · 2024Article
- Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging.Diagnostics (Basel, Switzerland) · 2024Review
- Neurological features of Hansen disease: a retrospective, multicenter cohort study.Scientific reports · 2024Article
- Clinicopathological characteristics and prognosis in patients with monoclonal gammopathy and renal damage in central China: a multicenter retrospective cohort study.Scientific reports · 2024Article
- Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.Hematology/oncology clinics of North America · 2024Review
- Case Report: Application ofFrontiers in nuclear medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Monoclonal gammopathies comprise a spectrum of clonal plasma cell disorders that include monoclonal gammopathy of undetermined significance, multiple myeloma, and Waldenström macroglobulinemia. In this review, we outline the epidemiology, etiology, classification, diagnosis, and treatment of monoclonal gammopathy-associated peripheral neuropathy. Monoclonal gammopathy of undetermined significance is relatively common in the general population, with a prevalence of 3% to 4% among individuals older than age 50 years. Therefore, the presence of M protein in a patient with neuropathy does not automatically indicate a causal relationship. Monoclonal gammopathy-associated peripheral neuropathy is often a difficult diagnosis with limited treatment options. Studies addressing the optimal approach to diagnosis and management of this entity are limited. In addition to a review of the literature, we present a diagnostic approach to patients with monoclonal gammopathy-associated peripheral neuropathy and discuss available data and options for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.